Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases

NCT01798108 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01798108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01798108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
August 14, 2001
Completion date
June 25, 2003
Enrollment
31 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis